Breast Surgery Practice Questions

Q: What is the most malignant type of carcinoma of the breast?

Mastitis carcinomatosa. **Explanation:** **Mastitis carcinomatosa**, also known as **Inflammatory Breast Cancer (IBC)**, is the most aggressive and malignant form of breast cancer. It is characterized by rapid clinical onset, where the breast appears red, swollen, and warm, mimicking an infection (mastitis). The underlying pathology involves the widespread blockage of **dermal lymphatics** by tumor emboli, rather than true inflammation. It is classified as T4d in the TNM staging system and is considered systemic at the time of diagnosis, carrying the poorest prognosis among all breast malignancies. **Analysis of Incorrect Options:** * **Paget’s Disease:** This is a superficial manifestation of an underlying ductal carcinoma (usually DCIS or invasive ductal carcinoma). While it indicates malignancy, it is localized to the nipple-areola complex and is not inherently the "most malignant" form. * **Anaplastic Carcinoma:** While these tumors show high-grade cytological features and poor differentiation, they do not typically exhibit the rapid, diffuse lymphatic spread and dismal survival rates characteristic of inflammatory breast cancer. * **Scirrhous Carcinoma:** This is an older term for Invasive Carcinoma of No Special Type (NST) with significant desmoplasia (fibrosis). It is the most common type of breast cancer but is less aggressive than the inflammatory variant. **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Hallmark:** *Peau d'orange* (orange peel appearance) due to cutaneous edema from lymphatic obstruction. * **Diagnosis:** Requires a full-thickness **punch biopsy** of the skin to demonstrate tumor emboli in dermal lymphatics. * **Management:** It is never treated with primary surgery. The standard of care is **Neoadjuvant Chemotherapy (NACT)** followed by Modified Radical Mastectomy (MRM) and Radiotherapy.

Q: A 4 cm breast nodule with an ipsilateral mobile lymph node in the axilla, what is the correct TNM staging?

T2N1M0. ### Explanation The TNM staging system for breast cancer is a cornerstone of surgical oncology. To solve this question, we must break down the clinical findings based on the AJCC 8th Edition criteria. **1. Why T2N1M0 is correct:** * **T (Tumor Size):** The nodule is **4 cm**. T2 is defined as a tumor >2 cm but ≤5 cm in its greatest dimension. * **N (Nodal Status):** The presence of an **ipsilateral mobile lymph node** in the axilla corresponds to **N1**. (N2 would involve fixed/matted nodes or internal mammary involvement). * **M (Metastasis):** In the absence of mentioned distant spread, it is staged as **M0**. * Combining these, the stage is **T2N1M0**. **2. Why other options are incorrect:** * **T2N2M0:** Incorrect because N2 requires "fixed" or "matted" axillary nodes, or clinically detected internal mammary nodes in the absence of axillary nodes. "Mobile" nodes are strictly N1. * **T1N1M0:** Incorrect because T1 is defined as a tumor ≤2 cm. This patient’s tumor is 4 cm. * **T3N2M1:** Incorrect on all counts. T3 is >5 cm; N2 implies fixed nodes; M1 implies distant metastasis (not mentioned). **Clinical Pearls for NEET-PG:** * **T-Staging Cheat Sheet:** T1 (≤2 cm), T2 (2–5 cm), T3 (>5 cm), T4 (Extension to chest wall/skin, regardless of size). * **N-Staging Key:** N1 = Mobile axillary nodes; N2 = Fixed/Matted axillary nodes; N3 = Supraclavicular, infraclavicular, or internal mammary + axillary nodes. * **Inflammatory Carcinoma:** Always staged as **T4d**, regardless of the actual size of the underlying mass. * **Dimpling vs. Peau d'orange:** Skin dimpling (tethering to Cooper’s ligament) does not change T-stage, but *Peau d'orange* or skin ulceration classifies it as T4.

Q: Which of the following statements regarding Paget's disease of the breast is true?

It presents with nipple-areolar eczematous changes.. **Explanation:** **Paget’s disease of the breast** is a rare manifestation of breast cancer characterized by the presence of malignant **Paget cells** (large, pale cells with prominent nucleoli) within the epidermis of the nipple-areolar complex. 1. **Why Option B is Correct:** The hallmark clinical presentation is an **eczematous-like lesion** of the nipple that may spread to the areola. It typically presents with erythema, scaling, crusting, or ulceration. Unlike simple eczema, Paget’s disease usually starts at the nipple and spreads peripherally, and it does not respond to topical steroids. 2. **Why the Other Options are Incorrect:** * **Option A:** There is **no clinical or pathological link** between Paget’s disease of the breast and Paget’s disease of the bone (a disorder of bone remodeling). They simply share the same namesake (Sir James Paget). * **Option C:** While Paget’s disease is associated with underlying **Ductal Carcinoma in Situ (DCIS)** in about 40% of cases, the remaining 60% have an underlying **Invasive Ductal Carcinoma (IDC)**. Therefore, axillary lymph node involvement is possible and depends on the stage of the underlying malignancy. * **Option D:** It is rare, accounting for only **1–4%** of all newly diagnosed breast cancers, not 10–15%. **High-Yield Clinical Pearls for NEET-PG:** * **Pathogenesis:** The "Epidermotropic Theory" suggests cancer cells migrate from underlying lactiferous ducts to the nipple skin. * **Diagnosis:** A **full-thickness punch biopsy** of the nipple is the gold standard. * **Key Histology:** PAS-positive, diastase-resistant cells (due to mucin content). * **Management:** Requires evaluation for underlying malignancy via mammography/MRI. Treatment involves mastectomy or breast-conserving surgery (central lumpectomy) plus radiotherapy.

Q: In inflammatory carcinoma of the breast with axillary metastasis, what is the treatment of choice?

None of the above. **Explanation:** The treatment of choice for **Inflammatory Breast Cancer (IBC)** is a multimodal approach, and the correct sequence is critical. The correct answer is "None of the above" because all listed options suggest primary surgery (mastectomy) as the first step, which is contraindicated in IBC. **1. Why "None of the above" is correct:** Inflammatory Breast Cancer is considered **Locally Advanced Breast Cancer (LABC)** and is staged as **T4d**. Because it is characterized by dermal lymphatic invasion and high systemic risk, the standard of care is **Multimodal Therapy** in a specific sequence: * **Step 1:** Neoadjuvant Chemotherapy (NACT) – to downstage the tumor and treat micrometastases. * **Step 2:** Modified Radical Mastectomy (MRM) – performed only if there is a good clinical response to NACT. * **Step 3:** Post-operative Radiotherapy – to reduce local recurrence. **2. Why other options are incorrect:** * **Options A, B, and C** all propose immediate surgery (Radical or Simple Mastectomy). In IBC, the skin is heavily involved with "cancerous lymphangitis." Primary surgery is avoided because it often results in positive margins, poor wound healing, and rapid local recurrence. Simple mastectomy (Option C) is also inappropriate as it does not address the axillary metastasis. **Clinical Pearls for NEET-PG:** * **Hallmark Sign:** *Peau d'orange* (due to dermal lymphatic obstruction). * **Diagnosis:** Requires a full-thickness **skin punch biopsy** showing tumor emboli in dermal lymphatics. * **Staging:** Always Stage IIIB (if N0-N2) or Stage IIIC (if N3). It is the most aggressive form of breast cancer. * **Surgery Type:** If surgery is performed after NACT, it must be **MRM**. Breast-conserving surgery is contraindicated in IBC.

Q: A 65-year-old woman with a 5 mm tubular cancer, ER positive, PR positive, and a negative sentinel lymph node, undergoes a lumpectomy and sentinel lymph node biopsy. What adjuvant treatment should be recommended?

Radiotherapy and hormonal therapy. ### Explanation The management of early-stage breast cancer is determined by the tumor size, nodal status, and receptor profile. This patient has a **T1a (5 mm), N0, ER/PR-positive** breast cancer. **1. Why Option D is Correct:** * **Radiotherapy:** The patient underwent a **Lumpectomy** (Breast Conserving Surgery - BCS). A fundamental principle in breast surgery is that BCS must always be followed by **Whole Breast Irradiation (WBI)** to reduce the risk of local recurrence. * **Hormonal Therapy:** Since the tumor is **ER/PR positive**, adjuvant endocrine therapy (e.g., Aromatase Inhibitors or Tamoxifen) is indicated to reduce the risk of both ipsilateral recurrence and contralateral new primary breast cancers. **2. Why Other Options are Incorrect:** * **Option A:** Chemotherapy is generally omitted in "favorable" histologies like **Tubular carcinoma**, especially when the tumor is 70 years with small, node-negative, ER+ tumors) where the absolute benefit of radiation is minimal. At 65, radiotherapy remains the standard of care post-BCS. **3. Clinical Pearls for NEET-PG:** * **Tubular Carcinoma:** A "favorable" histological subtype of invasive ductal carcinoma with an excellent prognosis. * **BCS Equation:** BCS + Radiotherapy = Modified Radical Mastectomy (MRM) in terms of overall survival. * **Sentinel Lymph Node Biopsy (SLNB):** Indicated for all clinically N0 patients to avoid the morbidity of Axillary Lymph Node Dissection (ALND). * **Adjuvant Endocrine Therapy:** Standard duration is 5 years; Aromatase Inhibitors (Anastrozole/Letrozole) are preferred in postmenopausal women.

Q: Which of the following is NOT a treatment for gynecomastia?

None of the above. **Explanation:** Gynecomastia is the benign proliferation of glandular breast tissue in males. The management strategy depends on the underlying cause, the duration of the condition, and the patient's symptoms (pain or cosmetic distress). **Why "None of the above" is correct:** All the listed options (A, B, and C) are recognized and valid treatment modalities for gynecomastia. Since the question asks which is **NOT** a treatment, and all provided options are indeed treatments, "None of the above" is the correct choice. **Analysis of Options:** * **Hormonal Therapy (Option A):** Used primarily in the early "florid" phase (usually <1 year). Selective Estrogen Receptor Modulators (SERMs) like **Tamoxifen** are the most common medical treatments. Other options include Aromatase inhibitors or Danazol. * **Simple Mastectomy (Option B):** This involves the surgical removal of the breast tissue and is indicated for severe (Grade III) gynecomastia or when malignancy is suspected. * **Subcutaneous Liposuction Mastectomy (Option C):** This is the preferred surgical approach for cosmetic results. It combines liposuction (to remove fatty tissue) with a periareolar incision to excise the glandular disc (Webster’s incision). **NEET-PG High-Yield Pearls:** * **Most common cause:** Idiopathic, followed by persistent pubertal gynecomastia. * **Drugs causing gynecomastia:** Remember the mnemonic **"DISCO"**: **D**igoxin, **I**soniazid, **S**pironolactone (most common drug cause), **C**imetidine, **O**estrogens. * **Grading:** Simon’s Classification is used to grade the severity. * **Pathology:** Characterized by an increase in stroma and ducts; notably, **males do not develop acini/lobules** unless exposed to extreme progestational stimulation.

Q: Triple assessment of a breast lump includes all EXCEPT:

Bone scan. **Explanation:** The **Triple Assessment** is the gold standard protocol for the evaluation of any palpable breast lump. It is designed to achieve a diagnostic accuracy of over 99%. It consists of three essential components: 1. **Clinical Examination:** A detailed history and physical examination (palpation) by a clinician. 2. **Imaging:** Usually **Mammography** (in women >35 years) or **Ultrasonography** (in women <35 years or during pregnancy/lactation). 3. **Pathology:** Tissue diagnosis via **Fine Needle Aspiration Cytology (FNAC)** or, more commonly now, **Core Needle Biopsy (CNB)**. **Why Bone Scan is the correct answer:** A **Bone scan** is a staging investigation used to detect distant metastasis in confirmed cases of advanced breast cancer. It is *not* part of the initial diagnostic "triple assessment" used to determine whether a lump is benign or malignant. **Analysis of other options:** * **Clinical Examination (Option C):** The first step in assessment; helps categorize the lump as "benign," "suspicious," or "malignant." * **Mammography (Option D):** The radiological component. It helps identify microcalcifications and architectural distortions. * **FNAC (Option A):** The pathological component. While Core Biopsy is now preferred for providing architecture and receptor status (ER/PR/HER2), FNAC remains a classic component of the triple assessment mentioned in standard textbooks. **Clinical Pearls for NEET-PG:** * If all three components of the triple assessment suggest a benign lesion, the chance of malignancy is **<1%**. * If there is a **discordance** (e.g., clinical exam suggests malignancy but imaging is benign), an excisional biopsy is mandatory. * **Modified Triple Assessment:** Includes Core Needle Biopsy instead of FNAC. Core biopsy is superior as it can distinguish between *in-situ* and invasive carcinoma.

Question 1

Which of the following has the best prognosis?

Accepted Answer

<1 cm Size, Node -ve, ER/PR +ve, Her 2 Negative

Answer

<1 cm Size, Node -ve, ER/PR -ve, Her 2 Positive

Answer

<2 cm Size, Node -ve, ER/PR +ve, Her 2 Negative

Answer

<2 cm Size, Node -ve, ER/PR -ve, Her 2 positive

Question 2

What is the most malignant type of carcinoma of the breast?

Accepted Answer

Mastitis carcinomatosa

Answer

Paget's disease

Answer

Anaplastic carcinoma

Answer

Scirrhous carcinoma

Question 3

A 9-week pregnant lady presents with a 2.5 cm mass in the upper outer quadrant of her left breast. Ultrasound did not reveal any abnormality. What is the ideal management?

Accepted Answer

Finger-guided core biopsy

Answer

Aspiration of the cyst and reassurance

Answer

Follow-up one month after delivery

Answer

Mammography

Question 4

A 4 cm breast nodule with an ipsilateral mobile lymph node in the axilla, what is the correct TNM staging?

Accepted Answer

T2N1M0

Answer

T2N2M0

Answer

T1N1M0

Answer

T3N2M1

Question 5

Which of the following statements regarding Paget's disease of the breast is true?

Accepted Answer

It presents with nipple-areolar eczematous changes.

Answer

It usually precedes the development of Paget's disease of bone.

Answer

It does not involve axillary lymph nodes because it is a manifestation of intraductal carcinoma only.

Answer

It accounts for 10-15% of all newly diagnosed breast cancers.

Question 6

In inflammatory carcinoma of the breast with axillary metastasis, what is the treatment of choice?

Accepted Answer

None of the above

Answer

Radical mastectomy plus chemotherapy

Answer

Radical mastectomy plus radiotherapy

Answer

Simple mastectomy plus radiotherapy

Question 7

A 65-year-old woman with a 5 mm tubular cancer, ER positive, PR positive, and a negative sentinel lymph node, undergoes a lumpectomy and sentinel lymph node biopsy. What adjuvant treatment should be recommended?

Accepted Answer

Radiotherapy and hormonal therapy

Answer

Chemotherapy and radiation

Answer

Radiation treatment only

Answer

Hormonal therapy only

Question 8

Paget's disease of the breast is associated with which of the following?

Accepted Answer

Ductal carcinoma in situ

Answer

Lobular carcinoma in situ

Answer

Phyllodes tumor

Answer

Mondor's disease

Question 9

Which of the following is NOT a treatment for gynecomastia?

Accepted Answer

None of the above

Answer

Hormonal therapy

Answer

Simple mastectomy

Answer

Subcutaneous liposuction mastectomy

Question 10

Triple assessment of a breast lump includes all EXCEPT:

Accepted Answer

Bone scan

Answer

Fine Needle Aspiration Cytology (FNAC)

Answer

Clinical examination

Answer

Mammography

Breast Surgery — MCQs

Breast Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?